You are here » Home » Companies » Company Overview » Gufic BioSciences Ltd

Gufic BioSciences Ltd.

BSE: 509079 Sector: Health care
NSE: GUFICBIO ISIN Code: INE742B01025
BSE 00:00 | 20 Jul 111.15 -2.60
(-2.29%)
OPEN

112.50

HIGH

112.60

LOW

110.40

NSE 00:00 | 20 Jul 111.15 -2.85
(-2.50%)
OPEN

112.95

HIGH

113.05

LOW

110.30

OPEN 112.50
PREVIOUS CLOSE 113.75
VOLUME 8882
52-Week high 164.35
52-Week low 64.25
P/E 56.71
Mkt Cap.(Rs cr) 860
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 112.50
CLOSE 113.75
VOLUME 8882
52-Week high 164.35
52-Week low 64.25
P/E 56.71
Mkt Cap.(Rs cr) 860
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Gufic BioSciences Ltd. (GUFICBIO) - Company History

Gufic Biosciences (GBL) is a result of a reverse merger of itself with Central Finance. The promoters of GBL took over Central Finance at Rs 40-42 per share and then got GBL listed on BSE. The Choksi and Gandhi family, the promoters of GBL, have a long-standing presence in the pharma industry. In 1960, the family set up a joint venture company called Lyka Labs. In 1976, they decided to part ways and the Choksi family took over the manufacturing facility and the Gufic group of companies was born. Initially known as Gujarat Fine Chemicals, the first foray of the Gufic group was in the manufacture of various bulk drugs. The company later entered the formulation market. Currently, the overall profile of GBL comprises ethical products, herbal products, consumer products and bulk drugs that are sold in the domestic and the international markets. Over the past several years, the company have a known reputation of creating brands that have vaulted to leadership positions in the category in which they have been marketed. To mention a few names: Shapers (sanitary napkins), Onergy, and Stretch nil. In the year 2000, the company issued Bonus Equity Shares in proportion of five Equity shares for every two Equity shares held. Gufic has divested brands in the ethical pharma business in a seller's market. The company plan to invest further in R&D activities and aggressively enter the herbal product and consumer product segments, where it foresee a huge potential. While benefiting from the rich, traditional knowledge base in India, it would like to operate from an area of strength in the herbal products segment.